Ligand Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ligand Pharma (LGND) Tops Q4 EPS by 52c
February 7, 2019 4:30 PM ESTLigand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.70, $0.52 better than the analyst estimate of $1.18. Revenue for the quarter came in at $59.6 million versus the consensus estimate of $51.26 million.
GUIDANCE:
Ligand Pharma sees FY2019 EPS of $6.05, up from $5.50 and versus the... More
